Roscoe, J.A., Garland, S.N., Heckler, C.E., Perlis, M.L., Peoples, A.R., Shayne, M., . . . Morrow, G.R. (2015). Randomized placebo-controlled trial of cognitive behavioral therapy and armodafinil for insomnia after cancer treatment. Journal of Clinical Oncology, 33, 165–171.
DOI Link
Study Purpose
To evaluate whether cognitive behavioral therapy for insomnia (CBT-I) in combination with a wakefulness-promoting agent, armodafinil, results in better insomnia outcomes in cancer survivors compared to CBTI-I alone
Intervention Characteristics/Basic Study Process
Interventions used in this study included CBT-I and armodafinil. Seven standard CBT-I sessions following a published treatment manual were delivered in person (days 1, 2, and 4 for a duration of 30–60 minutes) and via telephone (days 3, 5, and 6 for a duration of 15–30 minutes). Participants began with a 50 mg dose of a single-isomer formulation of modafinil (armodafinil) given between 7 and 9 a.m. with a placebo given between 12 and 2 p.m. After three days, armodafinil was given in the morning and afternoon for 40 days followed by four days of twice-per-day armodafinil at 50 mg. All participants received sleep hygiene guidelines at the time of consent. Computer-generated randomization assigned participants to one of four groups: CBT-I, armodafinil, CBT-I plus armodafinil, or neither. All participants who did not receive armodafinil were given a placebo.
Sample Characteristics
-
N = 73
-
MEAN AGE = 56 years
-
MALES: 12.5%, FEMALES: 87.5%
-
KEY DISEASE CHARACTERISTICS: Self-reported insomnia for at least three months that was caused or worsened by any cancer and its treatment; chemotherapy or radiation therapy completed greater than one month prior and no measurable disease; no sleep aids one week before baseline and throughout 11-week study
-
OTHER KEY SAMPLE CHARACTERISTICS: 68% breast cancer; original protocol called for only breast cancer but was broadened to include any cancers
Setting
-
SITE: Multi-site
-
SETTING TYPE: Outpatient
-
LOCATION: Two northeastern cities in the United States
Phase of Care and Clinical Applications
-
PHASE OF CARE: Late effects, survivorship
Study Design
Randomized, placebo-controlled trial
Measurement Instruments/Methods
-
Insomnia Severity Index (ISI)
-
Pittsburgh Sleep Quality Index (PSQI)
-
Demographics, clinical information, and sleep history
Results
Analyses controlling for baseline differences showed that both the CBT-I plus armodafinil (p = 0.001) and CBT-I plus placebo (p = 0.010) groups experienced significantly greater reductions in insomnia severity postintervention than the placebo group with effect sizes of 1.31 and 1.02, respectively. Similar improvements were seen for sleep quality. Gains on both measures persisted three months later. CBT-I plus armodafinil was not significantly different from CBT-I plus a placebo (p = 0.421), and armodafinil alone was not significantly different from a placebo alone (p = 0.584).
Conclusions
CBT-I results in significant and durable improvements in insomnia and sleep quality. Armodafinil did not significantly improve the efficacy of CBT-I or independently affect insomnia or sleep quality.
Limitations
Nursing Implications
Considering the prevalence of insomnia in patients with cancer and survivors, the potential for poorer outcomes if insomnia remains untreated, and the efficacy of CBT-I in treating chronic insomnia, it is desirable that providers and patients obtain increased access to evidence-based nonpharmacologic sleep interventions as an integral part of comprehensive cancer care. The findings of this study demonstrated that the addition of armodafinil to CBT-I treatment did not improve results for sleep.